We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $168M
1-Year Est. Return 60.36%
This Fund
S&P 500
This Quarter Est. Return
-12.56%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$212M
AUM Growth
-$64.6M
Cap. Flow
-$15M
Cap. Flow %
-7.08%
Top 10 Hldgs %
72.97%
Holding
103
New
14
Increased
10
Reduced
14
Closed
19

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2M
2
MYGN icon
Myriad Genetics
MYGN
+$1.92M
3
COGT icon
Cogent Biosciences
COGT
+$1.67M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.38M
5
TECX
Tectonic Therapeutic
TECX
+$1.3M

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$5.56M
2
VRNA
Verona Pharma
VRNA
+$4.26M
3
ICLO icon
Invesco AAA CLO Floating Rate Note ETF
ICLO
+$3.36M
4
JAAA icon
Janus Henderson AAA CLO ETF
JAAA
+$1.96M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.57M

Sector Composition

Rank Sector Weight
1 Healthcare 33.25%
2 Materials 20.41%
3 Financials 19.12%
4 Communication Services 8.29%
5 Industrials 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
26
Regeneron Pharmaceuticals
REGN
$69.9B
$1.27M 0.6%
+2,000
New +$1.38M
BMY icon
27
Bristol-Myers Squibb
BMY
$128B
$1.16M 0.55%
+19,000
New +$1.11M
COLL icon
28
Collegium Pharmaceutical
COLL
$1.15B
$1.15M 0.54%
38,473
+5,546
+17% +$169K
XBI icon
29
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$1.11M 0.52%
13,643
+3,643
+36% +$326K
RHP icon
30
Ryman Hospitality Properties
RHP
$8.51B
$1.1M 0.52%
12,000
– –
ABBV icon
31
AbbVie
ABBV
$461B
$1.06M 0.5%
5,037
– –
ACLX
32
DELISTED
Arcellx
ACLX
$984K 0.46%
+15,000
New +$1.02M
KMB icon
33
Kimberly-Clark
KMB
$36.8B
$853K 0.4%
6,000
– –
MGTX icon
34
MeiraGTx Holdings
MGTX
$1.16B
$848K 0.4%
125,010
+29,930
+31% +$201K
ATRC icon
35
AtriCure
ATRC
$1.85B
$794K 0.37%
+24,620
New +$914K
MREO
36
Mereo BioPharma
MREO
$46.8M
$719K 0.34%
319,337
-11,663
-4% -$33K
TECX
37
Tectonic Therapeutic
TECX
$588M
$708K 0.33%
+40,000
New +$1.3M
DD icon
38
DuPont de Nemours
DD
$18.8B
$703K 0.33%
7,503
-408
-5% -$39.8K
CTVA icon
39
Corteva
CTVA
$59B
$695K 0.33%
11,051
-512
-4% -$31.7K
ATYR
40
aTyr Pharma
ATYR
$47.5M
$675K 0.32%
223,407
-84,726
-27% -$309K
AUTL
41
Autolus Therapeutics
AUTL
$405M
$651K 0.31%
+420,000
New +$853K
MDLZ icon
42
Mondelez International
MDLZ
$77.5B
$611K 0.29%
9,000
– –
INZY
43
DELISTED
Inozyme Pharma
INZY
$606K 0.29%
666,204
-28,796
-4% -$39.9K
MSFT icon
44
Microsoft
MSFT
$2.89T
$601K 0.28%
1,600
– –
AAPL icon
45
Apple
AAPL
$4.94T
$554K 0.26%
2,494
– –
IBM icon
46
IBM
IBM
$206B
$533K 0.25%
2,142
– –
XENE icon
47
Xenon Pharmaceuticals
XENE
$6.38B
$532K 0.25%
15,866
-5,000
-24% -$190K
CNQ icon
48
Canadian Natural Resources
CNQ
$95B
$517K 0.24%
16,800
– –
SLDB icon
49
Solid Biosciences
SLDB
$804M
$488K 0.23%
+132,000
New +$565K
HELP
50
Cybin Inc
HELP
$493M
$424K 0.2%
66,880
+6,434
+11% +$55.7K
1
2
3 4 5

Similar funds

DI
Disciplined Investors Waco, Texas $168M AUM 23.6% 1-Year Est. Return
WFS
Widmann Financial Services Bowie, Maryland $168M AUM 24.36% 1-Year Est. Return
CCG
Catalina Capital Group Torrance, California $168M AUM 16.69% 1-Year Est. Return
7CM
7G Capital Management New York $168M AUM 45.68% 1-Year Est. Return
MAG
Meadowbrook Advisors Group Bedminster, New Jersey $168M AUM
PFA
Presper Financial Architects Akron, Ohio $168M AUM 12.94% 1-Year Est. Return
CW
Code Waechter Tampa, Florida $168M AUM 15.56% 1-Year Est. Return
IWA
Integrity Wealth Advisors Ventura, California $168M AUM 18.33% 1-Year Est. Return

David M. Knott Jr's Q1 2025 Portfolio in Review

As of Q1 2025, David M. Knott Jr held 103 positions worth $212M, down 23% from $277M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

David M. Knott Jr withdrew a net $15M in Q1 2025, closing 19 positions and reducing 14 holdings. Its most notable exit was Viking Therapeutics, an estimated $1.57M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 26% a quarter earlier, followed by Materials and Financials.

Against the trend, David M. Knott Jr opened a new position in Ultragenyx Pharmaceutical worth $1.74M.

  • David M. Knott Jr's largest Q1 2025 buy was Ultragenyx Pharmaceutical: 48,000 shares worth $1.74M.
  • David M. Knott Jr added most to Protagonist Therapeutics in Q1 2025, an estimated $990K increase.
  • David M. Knott Jr's biggest Q1 2025 reduction was Calumet Specialty Products, cutting an estimated $5.56M.
  • David M. Knott Jr fully exited Viking Therapeutics in Q1 2025, selling an estimated $1.57M.
  • David M. Knott Jr's ten largest holdings make up 73% of its $212M portfolio in Q1 2025.
  • David M. Knott Jr opened 14 new positions and closed 19 in Q1 2025.
  • David M. Knott Jr's portfolio value fell 23% quarter-over-quarter to $212M.

Based on David M. Knott Jr's 13F filing for Q1 2025, filed 12 May 2025.